Navigation Links
ProFibrix Steps up Recombinant Fibrinogen Program With PER.C6(R) License From Crucell
Date:1/13/2009

LEIDEN, The Netherlands, January 13 /PRNewswire/ -- ProFibrix B.V., today announced that it has concluded a commercial license agreement with Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) for PER.C6(R), a unique human protein production platform. The PER.C6(R) platform allows ProFibrix to manufacture recombinant human fibrinogen at levels that support the development and commercial roll-out of new products. Fibrinogen is at the heart of all ProFibrix products and is an essential part of nature's own injury-repair mechanism. The company's lead product Fibrocaps(TM) is based on fibrinogen derived from human blood plasma and is a unique dry powder topical hemostat that stops acute and severe bleeding during surgery or after trauma injury. Initially recombinant fibrinogen will be developed for systemic applications in hemostasis and later on for the development of tissue repair products.

Jaap Koopman, Ph.D., Chief Executive Officer, said: "The PER.C6(R) license gives us access to a manufacturing platform that has already been successfully tested by ProFibrix for high expression of biologically active recombinant fibrinogen. Our Chief Technology Officer Dr. Bram Bout was one of the inventors of PER.C6(R) while at Crucell. His intimate knowledge of the platform in combination with our substantial in-house expertise on the biology of fibrinogen provides us with a strong competitive position in the hemostasis market."

Jan Ohrstrom, MD, Chief Operational Officer, said: "We believe recombinant fibrinogen has the potential to become a breakthrough product in hemostasis and tissue repair. We intend to develop a systemic hemostat product based on recombinant fibrinogen to treat or prevent bleeding in patients with low fibrinogen levels."

About ProFibrix

ProFibrix was founded in 2004 and is headquartered in Leiden, The Netherlands, with a subsidiary in Seattle, WA. The company leverages its expertise in fibrinogen technology to develop and market innovative products for the hemostasis and regenerative medicine markets. Human fibrinogen plays a pivotal role in blood clotting and tissue healing. ProFibrix is led by a team with extensive commercial, clinical and scientific experience in the hemostasis field. Fibrocaps, the company's lead product, is based on a mixture of fibrinogen and thrombin and is a unique dry powder topical tissue sealant that stops acute and severe bleeding after trauma injury or during surgery. Fibrocaps has major advantages over existing liquid tissue sealants: It is easier to prepare and use, is more stable and effective, and can be applied in various ways, including in sprays or bandages. To support the development of its pipeline, ProFibrix is establishing a recombinant fibrinogen production platform in human PER.C6(R) cells that is expected to go into GMP production in 2010.


'/>"/>
SOURCE ProFibrix B.V.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Consensus Document Outlines Practical Steps for Reducing Gastrointestinal Risks of Antiplatelet and NSAID Use
2. Steps Toward Stopping Autoimmune Disease: International Consortium Identifies Genes Linked to Lupus
3. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
4. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
5. AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
6. Baxter Announces Recombinant Factor IX Development Program For Hemophilia B
7. CSL Behring Study in Animal Models Shows Feasibility of Developing a Half-Life Extended Recombinant FVIIa that Retains Biologic Activity
8. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
9. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
10. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
11. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... NEW YORK , Jan. 23, 2017 /PRNewswire/ ... a long way from conventional syringes with vials ... free systems. These modern devices have become preferred ... demand for prefilled syringes has been rising strongly ... of healthcare facilities are now adopting this format ...
(Date:1/24/2017)... , January 23, 2017 ... Growth A majority of medicines ... formulating Active Pharmaceutical Ingredients (API), and such processes require ... glycol. Production of pharmaceutical solvents continues to ... excluding Japan (APEJ) region as ...
(Date:1/23/2017)... 23, 2017 Endo International plc (NASDAQ / ... today filed a joint motion in the U.S. District ... seeking the entry of a ten-year Stipulated ... disputes between the FTC and Endo relating to the ... its Opana® ER and Lidoderm® products.  It also resolves ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... January 23, 2017 , ... Zachary Cattell, President of the ... healthcare industry expert at the 2017 Sector Summit hosted by Ivy Tech Community ... host Gerry Dick, will feature an employer and an association representative from five ...
(Date:1/23/2017)... ... January 23, 2017 , ... Moisture measurement is a necessary ... is paramount to success. Selecting an inappropriate measurement method can cause costly errors, ... the same equipment. Rare or expensive substances are wasted and production may even ...
(Date:1/23/2017)... California (PRWEB) , ... January 23, 2017 , ... "ProRandom is a set of camera ... to create dynamic looks in Final Cut Pro X," said Christina Austin - CEO of ... up to two layers of text with video footage. ProRandom works by using a ...
(Date:1/23/2017)... IL (PRWEB) , ... January ... ... and Education Foundation (OREF), in partnership with the American Society of Anesthesiologists® ... Safety Foundation (APSF), the American Academy of Orthopaedic Surgeons (AAOS) and the ...
(Date:1/23/2017)... , ... January 23, 2017 , ... “The Inn at the Mill”: a story ... fears in her quest to become happy and content. , “The Inn at the ... has also lived in Germany and Vermont and is now living in Berks County on ...
Breaking Medicine News(10 mins):